Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the second tranche of its previously announced non-brokered private placement financing (the "Financing") (see news release dated November 23, 2021 and December 23, 2021) by issuing 37,348,532 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $1,120,455.96 (the "Second Tranche"). In total, the Company has issued 109,032,378 Units for gross proceeds of $3,270,971.34 under the entire private placement financing. The Financing has been oversubscribed by $270,971.34

Each Unit in the Second Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

Under the Second Tranche, the Company paid finders' fee of $4,900 and 303,338 non-transferable warrants to Clarus Securities Inc., $7,035 and 234,500 non-transferable warrants to Research Capital Corporation., $3,500 and 116,666 non-transferable warrants to Canaccord Genuity Corp., and $10,500 and 350,000 non-transferable warrants to St. Peter Invest Corp.

The securities issued under the Second Tranche are subject to restrictions from resale for a period of four months and a day pursuant to applicable securities laws and the Exchange Hold Period.

As previously announced, the proceeds of the Financing will be directed primarily towards the purchase of new manufacturing equipment and facility upgrades to accommodate the manufacturing of plant-based entrees for the Company's 10-year exclusive manufacturing and distribution agreement with Flexitarian Foods Pty. Ltd., a division of Australia's largest plant-based manufacturer. Funds will also be allotted for inventory from key suppliers, investor relations fees of $90,000, repayment of accounts payable, general working capital purposes as well as accrued management fees of $278,371.71 and future management fees totaling $108,000.00 for three (3) senior management personnel through to the end of the Second Quarter of 2022.

Company CEO Mr. J. Craig Goodwin states, "The Company is pleased to close the second tranche of this capital raise, exceeding our target of three million dollars. The new manufacturing lines have now been ordered, and upgrades to our existing manufacturing facility to accommodate the production of our plant-based lines have begun".

Goodwin adds, "The first step is to install and commission two (2) packaging lines that will increase the opportunity to pursue retail opportunities. The first packaging line which was previously announced to be operational in January 2022, is now operational. Retail packaging will be finalized shortly, and we expect our retail packaging to be available by early February allowing us to begin penetrating the Canadian retail market. The second packaging line is scheduled to come on stream in February 2022. This second packaging line, greatly enhances our packaging capabilities by being able to accommodate a wide variety of packaging mediums, optimizing new opportunities specifically for the retail and direct to consumer markets. While we are building out our own manufacturing, we will continue to import product from our Australian partners. We look forward to providing updates in a timely manner as we embark on this most exciting opportunity".

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, President, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/683466/Naturally-Splendid-Closes-Second-Tranche-of-1120456-for-a-Total-Raise-of-3270971

News Provided by ACCESSWIRE via QuoteMedia

NSP:CA
The Conversation (0)
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Management Update

Naturally Splendid Management Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that Mr. George Ragogna will be stepping down as CFO and a Member of the Board of Directors effective immediately

Mr. Ragogna will remain with the Company as an Independent Consultant, focusing his efforts on logistics and our inventory management control system. Mr. Bryan Carson, current Executive VP and Company Co-founder, will step in as interim CFO.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the Company presented the PlanteinTM line of plant-based entrees at the Grocery Innovations Canada trade show on October 25 and October 26, 2022, at the Toronto Congress Centre

Grocery Innovations Canada, is one of Canada's premier grocery trade show events, bringing together manufacturers and retailers from not only Eastern Canada, but in fact from all across the country. Naturally Splendid featured the PlanteinTM line of plant-based products to retailers and distributors from across the country.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

VANCOUVER, BC / ACCESSWIRE/ September 6, 2022 / Naturally Splendid Enterprises Ltd.("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC Pink:NSPDF) is pleased to announce that Vegan Supply will carry a selection of PlanteinTM products for its retail and foodservice customers.

Vegan Supply, a Vancouver based company with both retail and foodservice distribution, began business in 2015 as the world's largest e-commerce marketplace exclusively providing their retail customers and foodservice clients with high-quality vegan products. Vegan Supply is listing five (5) PlanteinTM plant-based entrees: Nuggets, Schnitzel, Crumbed Tenders, Sweet Chili Tenders, and Crispy Burgers. The PlanteinTM line of products will be available through Vegan Supply's retail store in Vancouver, BC, their e-commerce platform, and marketed to their foodservice distribution network.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

This release acts as a correction for the release posted on 8/29/2022 at 10:30 PM EDT from Naturally Splendid Enterprises Ltd. announcing its second quarter results for 2022 due to an error in comments stated

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less
Man holds hand to head as fragments break off representing Alzheimer's disease.

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 6.9 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but because they do not affect the underlying causes of this neurodegenerative disease, they’re only a bandaid solution.

Keep reading...Show less

Latest Press Releases

Related News

×